BACKGROUND: Gaps in screening quality in community practice have been well documented. The authors examined recommended indicators of screening quality in the Centers for Disease Control and Prevention's Colorectal Cancer Screening Demonstration Program (CRCSDP), which provided colorectal cancer screening and diagnostic services between 2005 and 2009 for asymptomatic, low-income, underinsured, or uninsured individuals at 5 sites around the United States. METHODS: For each client screened in the CRCSDP, a standardized set of colorectal cancer clinical data elements was collected. Data regarding client age, screening history, risk level, screening test indication, results, and recommendation for the next test were analyzed. For colonoscopies, data were analyzed regarding whether the cecum was reached, bowel preparation was adequate, and identified lesions were completely removed. RESULTS: Overall, 53% of the fecal occult blood tests (FOBTs) (2295 tests) distributed were completed and returned. At the 2 sites with adequate numbers of FOBTs, 77% and 97%, respectively, of clients with positive results received follow-up colonoscopies. Site-specific cecal intubation rates ranged from 90% to 98%. Adenoma detection rates were 32% for men and 21% for women. For approximately one-third of colonoscopies, the recommended interval to the next test was shorter than recommended by national guidelines. At some sites, endoscopists failed to report on the adequacy of bowel preparation and completeness of polyp removal. CONCLUSIONS: Cecal intubation rates and adenoma detection rates met recommended levels. The authors identified the need for improvements in the follow-up of positive FOBTs, documentation of important elements in colonoscopy reports, and recommendations for rescreening or surveillance intervals after colonoscopy. Monitoring quality indicators is important to improve screening quality.
BACKGROUND: Gaps in screening quality in community practice have been well documented. The authors examined recommended indicators of screening quality in the Centers for Disease Control and Prevention's Colorectal Cancer Screening Demonstration Program (CRCSDP), which provided colorectal cancer screening and diagnostic services between 2005 and 2009 for asymptomatic, low-income, underinsured, or uninsured individuals at 5 sites around the United States. METHODS: For each client screened in the CRCSDP, a standardized set of colorectal cancer clinical data elements was collected. Data regarding client age, screening history, risk level, screening test indication, results, and recommendation for the next test were analyzed. For colonoscopies, data were analyzed regarding whether the cecum was reached, bowel preparation was adequate, and identified lesions were completely removed. RESULTS: Overall, 53% of the fecal occult blood tests (FOBTs) (2295 tests) distributed were completed and returned. At the 2 sites with adequate numbers of FOBTs, 77% and 97%, respectively, of clients with positive results received follow-up colonoscopies. Site-specific cecal intubation rates ranged from 90% to 98%. Adenoma detection rates were 32% for men and 21% for women. For approximately one-third of colonoscopies, the recommended interval to the next test was shorter than recommended by national guidelines. At some sites, endoscopists failed to report on the adequacy of bowel preparation and completeness of polyp removal. CONCLUSIONS: Cecal intubation rates and adenoma detection rates met recommended levels. The authors identified the need for improvements in the follow-up of positive FOBTs, documentation of important elements in colonoscopy reports, and recommendations for rescreening or surveillance intervals after colonoscopy. Monitoring quality indicators is important to improve screening quality.
Authors: David A Lieberman; Douglas K Rex; Sidney J Winawer; Francis M Giardiello; David A Johnson; Theodore R Levin Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: Kathryn A Phillips; Su-Ying Liang; Uri Ladabaum; Jennifer Haas; Karla Kerlikowske; David Lieberman; Robert Hiatt; Mika Nagamine; Stephanie L Van Bebber Journal: Med Care Date: 2007-02 Impact factor: 2.983
Authors: David Lieberman; Marion Nadel; Robert A Smith; Wendy Atkin; Subash B Duggirala; Robert Fletcher; Seth N Glick; C Daniel Johnson; Theodore R Levin; John B Pope; Michael B Potter; David Ransohoff; Douglas Rex; Robert Schoen; Paul Schroy; Sidney Winawer Journal: Gastrointest Endosc Date: 2007-05 Impact factor: 9.427
Authors: Marion R Nadel; Jean A Shapiro; Carrie N Klabunde; Laura C Seeff; Robert Uhler; Robert A Smith; David F Ransohoff Journal: Ann Intern Med Date: 2005-01-18 Impact factor: 25.391
Authors: Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham Journal: Lancet Date: 1996-11-30 Impact factor: 79.321
Authors: Peter B Cotton; Patrick Connor; Daniel McGee; Paul Jowell; Nick Nickl; Steve Schutz; Joseph Leung; John Lee; Eric Libby Journal: Gastrointest Endosc Date: 2003-03 Impact factor: 9.427
Authors: Marion R Nadel; Zahava Berkowitz; Carrie N Klabunde; Robert A Smith; Steven S Coughlin; Mary C White Journal: J Gen Intern Med Date: 2010-04-10 Impact factor: 5.128
Authors: Sujha Subramanian; Sonja Hoover; Florence K L Tangka; Amy DeGroff; Cynthia S Soloe; Laura C Arena; Dara F Schlueter; Djenaba A Joseph; Faye L Wong Journal: Cancer Date: 2018-10-25 Impact factor: 6.860
Authors: Djenaba A Joseph; Reinier G S Meester; Ann G Zauber; Diane L Manninen; Linda Winges; Fred B Dong; Brandy Peaker; Marjolein van Ballegooijen Journal: Cancer Date: 2016-05-20 Impact factor: 6.860
Authors: Steven B Zeliadt; Richard M Hoffman; Genevieve Birkby; Jan M Eberth; Alison T Brenner; Daniel S Reuland; Susan A Flocke Journal: Am J Prev Med Date: 2018-02-21 Impact factor: 6.604
Authors: Marion R Nadel; Janet Royalty; Djenaba Joseph; Tanner Rockwell; William Helsel; William Kammerer; Simone C Gray; Jean A Shapiro Journal: Prev Chronic Dis Date: 2019-05-30 Impact factor: 2.830